Study to Assess Change in Disease Activity and Adverse Events of RINVOQ in Adult Participants With Ankylosing Spondylitis in the Real-World Japan

Launched by ABBVIE · Nov 7, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at how well a medication called Rinvoq works for adults with ankylosing spondylitis (AS), a type of inflammatory disease that mainly affects the spine. The study will involve about 100 participants in Japan who are starting treatment with Rinvoq as prescribed by their doctors. Researchers want to see how effective the medication is in reducing disease activity and whether there are any side effects over a period of up to 52 weeks.

To participate, individuals must have a confirmed diagnosis of ankylosing spondylitis and be receiving their first dose of Rinvoq. However, those who have previously used certain other medications or are involved in other clinical trials won’t be eligible. Throughout the study, participants will continue with their usual doctor visits to monitor their health, and they won’t face any additional burdens beyond what they would normally experience.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participant with clinical diagnosis of ankylosing spondylitis (AS) and meeting the modified New York Criteria for AS.
• • Participant who is administered the first dose of Rinvoq for AS.
• Exclusion Criteria:
• • Participant with prior treatment by JAK inhibitors.
• • Participant currently participating in another clinical study except non-interventional study.
• • Participant for whom upadacitinib is contraindicated.
• • Participants who are not registered within 14 days after initiation of Rinvoq treatment for AS.